Lucid Diagnostics (LUCD) director granted 123,000 restricted stock shares

Rhea-AI Filing Summary

Sparks Ronald M reported acquisition or exercise transactions in this Form 4 filing.

Lucid Diagnostics director Ronald M. Sparks received an equity award of 123,000 shares of common stock on February 20, 2026. The shares were granted at a price of $0.00 per share as restricted stock under the company’s 2018 Equity Plan.

Following this grant, Sparks directly owns 320,460 shares of common stock. The restricted stock has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed, meaning he must remain in service through that date to retain the award.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Sparks Ronald M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common stock	123,000	$0.00	--

Holdings After Transaction: Common stock — 320,460 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sparks Ronald M

(Last) (First) (Middle)

360 MADISON AVENUE

25TH FLOOR

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lucid Diagnostics Inc. [ LUCD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	02/20/2026		A		123,000(1)	A	$0	320,460	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed

	/s/ Michael A. Gordon, by power of attorney	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lucid Diagnostics (LUCD) report for Ronald M. Sparks?

Lucid Diagnostics reported that director Ronald M. Sparks received a grant of 123,000 shares of restricted common stock. The award was recorded at $0.00 per share and was issued under the company’s 2018 Equity Plan as equity-based compensation rather than a market purchase.

How many Lucid Diagnostics (LUCD) shares does Ronald M. Sparks own after this grant?

After the restricted stock grant, Ronald M. Sparks directly owns 320,460 shares of Lucid Diagnostics common stock. This total includes the newly awarded 123,000 restricted shares, which are subject to vesting and potential forfeiture if service requirements are not satisfied.

When do Ronald M. Sparks’ Lucid Diagnostics (LUCD) restricted shares vest?

The 123,000 restricted shares granted to Ronald M. Sparks are scheduled to vest on May 20, 2029. The award has a single vesting date, and the shares can be forfeited if he does not complete the requisite service period through that date.

What type of Form 4 transaction did Lucid Diagnostics (LUCD) disclose for Ronald M. Sparks?

The Form 4 shows an acquisition coded as “A,” representing a grant or award of securities. Specifically, Sparks received a grant of restricted common stock, classified as a non-derivative transaction and described as a grant, award, or other acquisition of shares.

Was cash paid for the Lucid Diagnostics (LUCD) restricted stock granted to Ronald M. Sparks?

No cash changed hands for this award; the transaction price per share is reported as $0.00. This indicates the shares were issued as restricted stock compensation under the 2018 Equity Plan rather than purchased on the open market or in a cash transaction.

What conditions apply to Ronald M. Sparks’ Lucid Diagnostics (LUCD) restricted stock grant?

The restricted stock is subject to forfeiture if the required service period is not completed. The grant has a single vesting date of May 20, 2029, meaning Sparks must satisfy service conditions through that date to retain the full 123,000-share award.